Cambridge Healthtech Institute’s 11th Annual

Kinase Inhibitor Chemistry
(키나아제 저해제 화학)

2020년 4월 14-15일




키나아제 저해제 Discovery 분야에서는 단독요법 및 다제 병용요법에서 이용되는 면역조절제의 설계, 염증 및 중추신경계 장애 등 만성질환 증상에 대한 대응, 알로스테릭 조절의 효과적인 이용, 공유결합 화합물 등에 관한 심층 연구가 진행되며 호황을 보이고 있습니다. 이번 컨퍼런스에서는 키나아제 개발 분야에서 인공지능의 역할, 약물 표적으로서의 RNA, 포스파타아제, 단백질 분해 유도제 등의 토픽에 관한 논의가 진행됩니다.


Preliminary Agenda

NEW TARGETS & PROMISING CANDIDATES

Targeted Therapy in Patients with PIK3CA-Related Overgrowth Syndrome

Guillaume Canaud, MD, PhD, Professor of Medicine, Hospital Necker Enfants Malades, Paris

Comprehensive Evaluation of CDK Inhibitor Landscape in Cells

Carrow Wells, Research Associate, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill

A Cdk9-PP1 Switch Regulates the Elongation-Termination Transition of RNA Polymerase II

Pabitra Parua, PhD, Research Fellow, Robert P. Fisher Lab, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai

Interfering with the Immune System: DMXD-011, a Potential Treatment for Systemic Lupus Erythematosus (SLE)

Trevor Perrior, MA, PhD, FRSC, CEO, Domainex Limited

NEW TOOLS AND STRATEGIES

Artificial Intelligence in Kinase Inhibitor Discovery 

Istvan J. Enyedy, PhD, Principal Scientist, Biogen

Discovery of Brain-Penetrant ASK1 Inhibitors for the Treatment of Neurological Diseases

Felix Gonzalez Lopez de Turiso, PhD, Team Leader, Medicinal Chemistry, Drug Discovery, Biogen

Targeting CDK Protein by Covalent Inhibitor and PROTAC Degrader

Tinghu Zhang, Scientist, Nathanael Gray Lab, Cancer Biology, Dana-Farber Cancer Institute/Harvard Medical School

TARGETED KINASE DEGRADATION STRATEGIES


New Activities for Cereblon Modulators

Philip Chamberlain, DPhil, Executive Director, Structural and Chemical Biology, Celgene

So Many Ubiquitin Ligases and So Few PROTACs: Carving a New Path with Novel Ligases

Tauseef Butt, PhD, President and CEO, Progenra Inc.

Molecular Mechanisms of Small Molecule-Mediated Ubiquitin Ligase Targeting

Eric S. Fischer, PhD, Assistant Professor, Cancer Biology/Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute/Harvard Medical School

Targeting Focal Adhesion Kinase with PROTACs: From Tool to in Vivo

Joao Nunes, PhD, Investigator, Protein Degradation Group, Medicinal Science and Technology, GSK Medicine Research Centre

ADME Properties of PROTACs and Oral Bioavailability Improvement Strategies

Upendra Dahal, PhD, Senior Scientist, Pharmacokinetics and Drug Metabolism, Amgen, Inc.

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.

Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English





메일링 서비스